OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Hematology & Oncology is 50. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Proteasome inhibition enhances oncolytic reovirus therapy in multiple myeloma independently of its direct cytotoxic effects	913
Mapping the cell therapy landscape: insights into clinical trials and regulatory advances in China	883
Retraction Note: m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and	861
Novel natural killer cell-based therapies for hematologic and solid malignancies: latest updates from ASCO 2024	847
Recent advances in targeting protein degradation for tumor immunotherapy	793
The Association of Agent Orange Exposure with the progression of monoclonal gammopathy of undetermined significance to multiple myeloma: a population-based study of Vietnam War Era Veterans	597
KRAS mutation detection by liquid biopsy for pancreatic ductal adenocarcinoma	448
1-year survival in haemophagocytic lymphohistiocytosis: a nationwide cohort study from England 2003–2018	432
Identification of restrictive molecules involved in oncolytic virotherapy using genome-wide CRISPR screening	386
Challenges and strategies in clinical applications of CAR-T therapy for autoimmune diseases	363
WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associ	358
The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency	355
Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies	346
Cytokines and cancer-associated fibroblasts	334
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy	333
Cancer vaccines: current status and future directions	301
Landscape of biallelic DNMT3A mutant myeloid neoplasms	300
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2	299
Evidence of SARS-CoV-2 spike protein on retrieved thrombi from COVID-19 patients	288
Overcome the challenge for intratumoral injection of STING agonist for pancreatic cancer by systemic administration	254
Comparative analysis of cancer cell responses to targeted radionuclide therapy (TRT) and external beam radiotherapy (EBRT)	253
Super-enhancer hijacking LINC01977 promotes malignancy of early-stage lung adenocarcinoma addicted to the canonical TGF-β/SMAD3 pathway	241
HCB101: a novel potent ligand-trap Fc-fusion protein targeting the CD47-SIRPα pathway with high safety and preclinical efficacy for hematological and solid tumors	240
Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, p	238
Hypoxia-induced exosomal circPDK1 promotes pancreatic cancer glycolysis via c-myc activation by modulating miR-628-3p/BPTF axis and degrading BIN1	237

Epigenetic regulation of diverse cell death modalities in cancer: a focus on pyroptosis, ferroptosis, cuproptosis, and disulfidptosis	236
Personalized nanovaccines for treating solid cancer metastases	221
A modular γδ TCR-T platform combining KRAS pMHC targeting with re-dosable mRNA engager redirection	218
Ferroptosis: principles and significance in health and disease	210
Cancer-associated fibroblast-specific lncRNA LINC01614 enhances glutamine uptake in lung adenocarcinoma	210
Recent advances in therapeutic strategies for non-small cell lung cancer	209
IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts	209
Targeted degradation of extracellular proteins: state of the art and diversity of degrader designs	198
Identifying long-term survivors and those at higher or lower risk of relapse among patients with cytogenetically normal acute myeloid leukemia using a high-dimensional mixture cure model	198
Outcomes of patients with acute myeloid leukemia and bone marrow fibrosis	196
Multiple myeloma risk linked to DNA damage response genes	193
Similar outcomes following non-first-degree and first-degree related donor haploidentical hematopoietic cell transplantation for acute leukemia patients in complete remission: a study from the Global	192
Non-invasive diagnosis of esophageal cancer by a simplified circulating cell-free DNA methylation assay targeting OTOP2 and KCNA3: a double-blinded, multicenter, prospective study	187
Unraveling the roles and mechanisms of mitochondrial translation in normal and malignant hematopoiesis	186
Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy	179
Recent advances in targeted strategies for triple-negative breast cancer	175
CD47 blockade-driven necroptosis complements BCL-2 inhibition-driven apoptosis in lymphoid malignancies	174
Small RNA modifications: regulatory molecules and potential applications	171
Correction: Non-invasive diagnosis of esophageal cancer by a simplified circulating cell-free DNA methylation assay targeting OTOP2 and KCNA3: a double-blinded, multicenter, prospective study	169
Genotype–phenotype associations within the Li-Fraumeni spectrum: a report from the German Registry	163
GAS6-based CAR-T cells exhibit potent antitumor activity against pancreatic cancer	162
The gynecologic tumor risk related to GLP-1 receptor agonists and SGLT2 inhibitors use: a network meta-analysis of 91 randomized controlled trials	155
Emerging artificial intelligence advances in oncology: latest updates from the 2026 AACR annual meeting	154
Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts	152
Menin inhibitors from monotherapies to combination therapies: clinical trial updates from 2024 ASH annual meeting	152
Development and validation of the post-CAR prognostic index for large B-cell lymphoma patients after CAR-T progression in third or later line treatment	149
Osteosarcoma with cell-cycle and fibroblast growth factor genomic alterations: case report of Molecular Tumor Board combination strategy resulting in long-term exceptional response	147
A single-cell transcriptomic map of the murine and human multiple myeloma immune microenvironment across disease stages	146
Target neutrophil heterogeneity and plasticity in cancer	143
LCN2 secreted by tissue-infiltrating neutrophils induces the ferroptosis and wasting of adipose and muscle tissues in lung cancer cachexia	142
Proteasome inhibition enhances the anti-leukemic efficacy of chimeric antigen receptor (CAR) expressing NK cells against acute myeloid leukemia	141
Recent advances in sarcoma therapy: new agents, strategies and predictive biomarkers	141
Novel potent molecular glue degraders against broad range of hematological cancer cell lines via multiple neosubstrates degradation	139
Targeting cuproptosis for cancer therapy: mechanistic insights and clinical perspectives	137
Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study	135
A single-cell and spatially resolved atlas of human osteosarcomas	135
Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis	134
Methyltransferase-like proteins in cancer biology and potential therapeutic targeting	133
Insights into next-generation immunotherapy designs and tools: molecular mechanisms and therapeutic prospects	129
Chemo-free treatment of adult patients with Ph-positive acute lymphoblastic leukemia: latest updates from the 2023 ASH annual meeting	126
Electrostatic anti-CD33-antibody–protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia	122
Targeting Claudin-18.2 for cancer therapy: updates from 2024 ASCO annual meeting	120
Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies	118
The functional and clinical roles of liquid biopsy in patient-derived models	115
Preclinical evaluation of combination nemtabrutinib and venetoclax in chronic lymphocytic leukemia	114
Echinomycin as a promising therapeutic agent against KSHV-related malignancies	113
New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting	109
CD20 xCD3 bispecific antibodies for large B cell lymphoma: latest updates from 2024 ASH annual meeting	109
Tucidinostat plus pediatric-inspired chemotherapy for newly diagnosed adult ETP-ALL/LBL: a single-arm, phase 2 trial	107
C3G promotes bone marrow adipocyte expansion and hematopoietic regeneration after myeloablation by enhancing megakaryocyte niche function	106

A clinical study of autologous chimeric antigen receptor macrophage targeting mesothelin shows safety in ovarian cancer therapy	106
Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II	105
JMJD4-demethylated RIG-I prevents hepatic steatosis and carcinogenesis	103
Gastric cancer treatment: recent progress and future perspectives	100
Genome-edited allogeneic CAR-T cells: the next generation of cancer immunotherapies	100
Challenges and new technologies in adoptive cell therapy	98
Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives	98
Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives	98
GVHD occurrence does not reduce AML relapse following PTCy-based haploidentical transplantation: a study from the ALWP of the EBMT	96
Reduced-dose chemotherapy and blinatumomab as induction treatment for newly diagnosed Ph-negative B-cell precursor acute lymphoblastic leukemia: a phase 2 trial	94
CD20-directed antibody-drug conjugates in non-hodgkin lymphoma: translating preclinical promise into clinical reality	91
The DAPK3-DCAF1 pathway regulates ZBP1 protein stability to orchestrate PANoptosis for ovarian cancer therapy	90
METTL16 promotes liver cancer stem cell self-renewal via controlling ribosome biogenesis and mRNA translation	89
Targeting GPRC5D for multiple myeloma therapy	88
Clinical benefit of PD-1 antibody plus chemotherapy in advanced HER2 negative gastric or gastro-oesophageal junction adenocarcinoma according to PD-L1 levels: Post-hoc analysis of RATIONALE-305 and po	87
Long-term survival with donor CD19 CAR-T cell treatment for relapsed patients after allogeneic hematopietic stem cell transplantation	85
RAS signaling in carcinogenesis, cancer therapy and resistance mechanisms	83
Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients	83
Metabolic reprogramming in the tumor microenvironment of liver cancer	83
First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors	83
Elevated plasma levels of IL-6 and MCP-1 selectively identify CML patients who better sustain molecular remission after TKI withdrawal	81
Broadly applicable TCR-based therapy for multiple myeloma targeting the immunoglobulin J chain	79
Myeloid-like tumor hybrid cells in bone marrow promote progression of prostate cancer bone metastasis	78
Large-scale real-life analysis of survival and usage of therapies in multiple myeloma	78
Correction : LINC01123, a c-Myc-activated long non-coding RNA, promotes proliferation and aerobic glycolysis of non-small cell lung cancer through miR-199a-5p/c-Myc axis	77
Correction: Large-scale real-life analysis of survival and usage of therapies in multiple myeloma	77
Correction: Immunosenescence: a key player in cancer development	75
Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease	75
A practical approach on the classifications of myeloid neoplasms and acute leukemia: WHO and ICC	73
PSMA-targeted CAR-macrophages drive glycolytic reprogramming for enhanced prostate cancer immunotherapy	73
The cGAS‒STING pathway in cancer immunity: mechanisms, challenges, and therapeutic implications	71
Replicon RNA vaccines: design, delivery, and immunogenicity in infectious diseases and cancer	70
Nanomaterials-driven in situ vaccination: a novel frontier in tumor immunotherapy	70
Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned	69
Advances in CAR-T cell therapy for hematologic and solid malignancies: latest updates from 2024 ESMO Congress	69
Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study	69
Advances in targeting histone deacetylase for treatment of solid tumors	67
Immune checkpoint of B7-H3 in cancer: from immunology to clinical immunotherapy	65
Racial disparities in clonal hematopoiesis and their impact on hematologic malignancies	65
Retraction Note: AMLnet, A deep-learning pipeline for the differential diagnosis of acute myeloid leukemia from bone marrow smears	63
Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry	61
Cancer stem cell plasticity: mechanisms, immune microenvironment crosstalk, and therapeutic implications	60
Long-term control of peritoneal metastases following claudin 18.2-targeted CAR T-Cell therapy in advanced gastric cancer	60
Targeting ERRα promotes cytotoxic effects against acute myeloid leukemia through suppressing mitochondrial oxidative phosphorylation	60
Novel clinical risk stratification and treatment strategies in relapsed/refractory peripheral T-cell lymphoma	59
Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a study from the ALWP/EBMT	57
Global status and attributable risk factors of breast, cervical, ovarian, and uterine cancers from 1990 to 2021	57
Development and application of nanomaterials, nanotechnology and nanomedicine for treating hematological malignancies	56
Safety and efficacy of amulirafusp alfa (IMM0306), a fusion protein of CD20 monoclonal antibody with the CD47 binding domain of SIRPα, in patients with relapsed or refractory B-cell non-Hodgkin lympho	56
Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2	55
The neuro-immune axis in cancer: from mechanisms to therapeutic opportunities	55
Integrated clinical and proteomic-based model for diagnostic and prognostic prediction in pRCC	55
Prognostic landscape of mitochondrial genome in myelodysplastic syndrome after stem-cell transplantation	51
The distinct roles of ROS in tumor immunity: from mechanisms to immunotherapeutic applications	50
Claudin18.2 positive gastric cancer: biology, tumor microenvironment, and therapeutic strategies	50
Luspatercept and imetelstat for myelodysplastic syndrome: updates from ASH 2025 annual meeting	50